Advances in the genetics and treatment of von Willebrand disease

Current Opinion in Pediatrics

Volumn 14, Issue 1, 2002, Pages 23-33

  Federici, Augusto B ^a   Mannucci, Pier Mannuccio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; ESTROGEN; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

BLEEDING DISORDER; BLEEDING TIME; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENETIC ANALYSIS; GENETIC VARIABILITY; HEMOSTASIS; HUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE TRANSFUSION; THROMBOSIS; VON WILLEBRAND DISEASE;

CHILD; DEAMINO ARGININE VASOPRESSIN; DELIVERY, OBSTETRIC; FACTOR VIII; FEMALE; HEMOSTATICS; HUMANS; PHENOTYPE; PREGNANCY; PRENATAL DIAGNOSIS; PREVALENCE; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0036190199     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200202000-00005     Document Type: Review

References (109)

1. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation
2. Von Willebrand disease
3. Diagnosis and management of von Willebrand disease
4. Impact, diagnosis and treatment of von Willebrand disease
5. Guidelines for diagnosis and management of von Willebrand disease in Italy
6. A revised classification of von Willebrand disease
7. Von Willebrand disease and quantitative variation of von Willebrand factor
8. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor
9. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (IIA) von Willebrand's disease
10. Heterogeneity of type I von Willebrand disease: Evidence for a subgroup with an abnormal von Willebrand factor
11. Type I von Willebrand disease, subtype "platelet low": Decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells
12. Genetics of classic von Willebrand's disease: I. Phenotypic variations within families
13. Serial studies in von Willebrand disease: Variability versus "variants."
14. The effect of ABO blood groups on the diagnosis of von Willebrand disease
15. On laboratory problems in diagnosing mild von Willebrand disease
16. Variant von Willebrand's disease: Characterization of two subtypes by analysis of multimeric composition of FVIII/vWF in plasma and platelets
17. Type II A VWD with apparent recessive inheritance
18. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: From the patient to the gene. INSERM nerwork on molecular abnormalities in von Willebrand disease
19. Impaired intracellular transport produced by a subset of type II A vWD mutations
20. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor
21. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit
22. Partial identification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis
23. Proteolytic cleavage of recombinant 2A von Willebrand factor mutants R834W and R834Q: Inhibition by doxycycline and by monoclonal antibody VP-1
24. Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease
25. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC
26. Defective dimerization of von Willebrand factor subunit due to a Cys to Arg mutation in type IID von Willebrand disease mutations
27. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease
28. VWF synthesized by endothelial cells from a patient with type II B supports platelet adhesion normally but has an increased affinity for platelets
29. Heterogeneity in type II B vWD: Two unrelated cases with no family history and mild abnormalities of ristocetin-induced interactions between vWF and platelets
30. Thrombocytopenia associated with pregnancy in a patient with type II B VWD
31. Spontaneous platelet aggregation during pregnancy in a patient wit vWD type II B can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa
32. Type II B Tampa: A variant of vWD with chronic thrombocytopenia, circulating platelet aggregates, and spontaneous platelet aggregation
33. A type 2B von Willebrand disease mutation (IIe546->Val) associated with an unusual phenotype
34. Von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure
35. Von Willebrand disease type B: A missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib
36. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of Von Willebrand factor (VWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of VWF
37. Type 2M-Milwaukee-1 von Willebrand disease: An in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets
38. Type 2M von Willebrand disease: F6061 and 1662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets
39. Von Willebrand's disease "Vicenza" with larger than normal (supranormal) von Willebrand factor multimers
40. New families with von Willebrand disease type 2M (Vicenza)
41. Von Willebrand disease type 2M "Vicenza" in Italian and German patients: Identification of the first candidate mutation (G3864A: R1205H) in 8 families
42. New variant of von Willebrand disease with defective binding to factor VIII
43. A new vWF defect in a patient with FVIII deficiency but with normal level and multimeric patterns of both plasma and platelet vWF: Characterization of abnormal vWF/FVIII interaction
44. Results of screening for von Willebrand disease type 2N in patients with suspected hemophilia A or von Willebrand disease type 1
45. Type 2N von Willebrand disease: Clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology
46. Nonsense mutations in the von Willebrand factor gene in patients with von Willebrand disease type III and type I
47. Characterization of the von Willebrand factor (VWF) gene in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin
48. Genetic heterogeneity of severe von Willebrand disease type III in the German population
49. Effects of the mutant von Willebrand factor gene in von Willebrand disease
50. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease
51. Precipitating antibodies to FVIII/von Willebrand factor in von Willebrand disease: Effects on replacement therapy
52. Antibodies to von Willebrand factor in von Willebrand disease
53. Gene deletion correlates with the development of alloantibodies in von Willebrand disease
54. Life-threatening reaction to FVIII concentrate in a patient with severe vWD and alloantibodies to von Willebrand factor
55. Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: Role of complement and alloantibodies to von Willebrand factor
56. Von Willebrand disease from 1926 to 1983
57. Epidemiological investigation of the prevalence of von Willebrand's disease
58. Prevalence of von Willebrand's disease among US adults
59. Prevalence of von Willebrand disease in children: A multiethnic study
60. Von Willebrand factor and its disorders: An overview of recent molecular studies
61. Frequency of the different types of von Willebrand disease in the GDR
62. Von Willebrand factor multimer pattern in von Willebrand disease
63. A study of von Willebrand disease in Jordan
64. The 20-year (1978-1998) natural history of von Willebrand disease in Italy: A multicentre retrospective analysis on diagnosis and therapy in 1234 patients
65. Von Willebrand's disease in Sweden
66. Prevalence of bleeding manifestations, hepatitis and alloantibodies to von Willebrand factor in 348 Iranian patients with type 3 von Willebrand disease
67. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease: Single center comparison of four different assays
68. Von Willebrand disease: A database of point mutation, insertions and deletions
69. A database of polymorphisms in the von Willebrand factor gene and pseudogene
70. Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gene
71. Report on a joint WHO/WFH meeting on the control of haemophilia: Carrier detection and prenatal diagnosis
72. Prenatal evaluation of fetus at risk for severe von Willebrand disease
73. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease
74. Management of inherited von Willebrand disease
75. The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, ATIII and OT in man
76. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells
77. A new pharmacological approach to the management of hemophilia and von Willebrand disease
78. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease
79. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand disease and haemophilia A
80. Hyponatremia and seizures in young children given DDAVP
81. Myocardial infarction in a patient with hemophilia A treated with DDAVP
82. Thrombosis following desmopressin for uremic bleeding
83. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type II B von Willebrand disease
84. DDAVP for type IIb von Willebrand disease
85. Platelet aggregation and pseudothrombocytopenia induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type II B von Willebrand disease
86. Biological effect of desmopressin in eight patients with type 2 N ("Normandy") von Willebrand disease
87. Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease
88. Biological response to desmopressin and its use in clinical practice: A retrospective study on 774 Italian patients with type 1 and 2 von Willebrand disease
89. Response to desmopressin in patients with clinically severe type 1 and 2 von Willebrand disease: Results of a multicentre European study
90. Correction of the hemostatic defects in von Willebrand disease
91. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease
92. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate
93. Biological effects of a S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease
94. Transfusion studies in von Willebrand disease: Effect on bleeding time and factor VIII
95. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease
96. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III
97. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: A cross-over randomized trial
98. Recommended protocol for the study of the ex vivo biological effects of virus-inactivated plasma concentrates in patients with von Willebrand disease
99. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease
100. Haemate P in children with von Willebrand disease
101. Experience with Haemate P in von Willebrand's disease in adults
102. Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): Estimation of the rate of factor VIIIC synthesis
103. Treatment of von Willebrand disease with a high purity Factor VIII/von Willebrand Factor concentrate in the treatment of von Willebrand disease: A prospective multicenter study
104. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease
105. Optimizing therapy of von Willebrand disease with a safe and pure von Willebrand factor concentrate: The experience of the European Community
106. DDAVP shortens the prolonged bleeding time of patients with severe von Willebrand disease treated with cryoprecipitate: Evidence for a mechanism of action independent of released von Willebrand factor
107. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease
108. Pregnancy in women with different types of von Willebrand disease